Pharmaceuticals

HISUN

HISUN to Release FY2026 Q1 Earnings on April 28 After-Market (BJT), Forecast EPS CNY 0.18

HISUN released FY2026 Q1 earnings on April 15 After-Market (BJT), actual revenue CNY 239.05 K, actual EPS CNY 0.31 (forecast EPS CNY 0.18)

HISUN released FY2025 annual earnings on April 7 After-Market (BJT), actual revenue CNY 10.55 B (forecast CNY 9.341 B), actual EPS CNY 0.46 (forecast CNY 0.35)

HISUN released FY2025 Q4 earnings on April 7 After-Market (BJT), actual revenue CNY 2.627 B, actual EPS CNY 0.064

HISUN to Release FY2025 Annual Earnings on April 8, After-Market (BJT), Forecast Revenue CNY 9.341 B, EPS CNY 0.35

Insilico Medicine and Huahai Pharmaceutical Co. Complete PCC Nomination within 8 Months of Collaboration

HISUN released FY2025 Q3 earnings on October 27 During-Market (BJT), actual revenue CNY 2.672 B, actual EPS CNY 0.1402 (forecast EPS CNY 0.12)

HISUN released FY2025 9 Months Earnings on October 27 During-Market (BJT), actual revenue CNY 7.923 B, actual EPS CNY 0.3981

HISUN to release FY2025 Q3 earnings report on October 28 during market hours (BJT), forecast EPS CNY 0.12

HISUN released FY2025 Q2 earnings on August 25 During-Market (BJT), actual revenue CNY 2.619 B, actual EPS CNY 0.0878 (forecast EPS CNY 0.14)

HISUN released FY2025 Semi-Annual Earnings on August 25 During-Market (BJT), actual revenue CNY 5.25 B, actual EPS CNY 0.2561

HISUN to Release FY2025 Semi-Annual Earnings Report on August 26, 2025 (BJT)

Hisun Pharmaceutical Struggles After Pfizer Split

Hisun Pharmaceutical Secretary Responds to Investor Inquiries on Product and Pipeline

Huazheng Pharmaceutical Obtains Approval for Bedaquiline Fumarate API

Hisun Pharmaceutical Secretary Responds to Drug Sales

Hisun Pharmaceutical Receives Approval for Clinical Trial of HS387

Haisong Pharmaceutical Expands Cooperation at CPHI Fair

Hisun Pharmaceutical Establishes Subsidiary to Enter Synthetic Biology

Haisun Pharmaceutical and Huizh International JV Synbio Subsidiary

688166

000919

600267

002361

603698

As of the midday close on April 15, the Shanghai Composite Index rose 0.37%, the Shenzhen Component Index fell 0.25%, and the GEM Index dropped 0.23%. Innovative drug concept stocks such as BrightGene, HISUN, and JINLING PHARM. performed strongly, hitting the limit up. Commercial aerospace concepts also continued to rise, with CETEC, Hualing Cables, and SHENJIAN GUFEN all hitting the limit up. In contrast, oil and gas stocks declined, with Meineng Energy touching the limit down; the lithium battery sector adjusted, with Haikexinyuan falling more than 10%. Overall, individual stocks showed more declines than gains, with total trading volume reaching 1.59 trillion yuan

Wallstreetcn

BrightGene

JINLING PHARM.

SHENJIAN GUFEN

CETEC

ChiNext

SSE Index

HUNAN VALIN WIRE&CABLE

WG Tech

Meineng Energy

Hi-Tech Spring

Shenzhen Index

April 15 Midday Market Review: GEM Index Opens High and Falls, Closing Down 0.23%; Innovative Drug Concepts Rally Collectively

HISUN released its annual report for 2025, expecting operating revenue of 10.55 billion yuan, a year-on-year increase of 2.03%; net profit excluding non-recurring items of 586 million yuan, a year-on-year increase of 36.11%. The company has increased its investment in research and development, with R&D expenses reaching 479 million yuan in 2025, a year-on-year increase of 33.79%. The financial structure continues to optimize, with a decrease in the asset-liability ratio and steady improvement in operational quality

Donews

HISUN's revenue in 2025 is expected to be 10.55 billion yuan

512290

159506

159570

Xinhua Pharmaceutical Wins NMPA Approval for New Electrolyte Injection

Tip Ranks

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP CSI Pharmaceuticals ETF

Bosera Hang Seng Health Care ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Universal 800 Health Care ETF

Xinhua Pharm

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Xinhua Pharmaceutical Wins NMPA Approval for New Electrolyte Injection

HISUN Animal Health collaborates with Zhongyu Pet Food to establish a pet prescription food company based on clinical data

China's pet prescription food welcomes a breakthrough player

HISUN announced that the company will commence its fourth share repurchase through centralized bidding starting from May 12, 2025, with the repurchase period ending on May 11, 2026. The expected amount is between 50 million yuan and 100 million yuan, intended for the employee stock ownership plan or equity incentive. As of the end of October 2025, the company has cumulatively repurchased 6,115,000 shares, accounting for 0.51% of the total share capital, with a total payment of 56.9915 million yuan, and the repurchase price ranging from 8.92 yuan/share to 10.55 yuan/share, in line with the established plan

Zhitong

HISUN: Has cumulatively spent CNY 56.9915 million to repurchase 0.51% of its shares

SNYNF

The negotiations for the national medical insurance catalog in 2025 entered their second day. Reporters observed that around 7:30 AM, companies were already waiting outside the National People's Congress conference center. Information verification for entry began around 8:00 AM. The companies participating in the negotiations this morning included Shenghe Pharmaceutical, HISUN, and Sanofi

Sanofi

On the morning of the second day of the National Conference in 2025: Shenghe Pharmaceutical, HISUN, and other pharmaceutical companies enter the venue

On October 30th, HISUN Pharmaceuticals and ShengZhao Pharmaceuticals held a cooperation signing ceremony in Taizhou, Zhejiang. According to the agreement, HISUN Pharmaceuticals and ShengZhao Pharmaceuticals will jointly invest in establishing a joint venture company in the Jiaojiang District of Taizhou City, focusing on the field of complex injectables. HISUN Pharmaceuticals plans to invest CNY 495 million for a 45% stake; ShengZhao Pharmaceuticals plans to invest CNY 605 million for a 55% stake. The joint venture will primarily engage in the research and development, production, and commercialization of 11 complex injectable products. In addition, HISUN Pharmaceuticals will have the priority cooperation rights for future related products from ShengZhao Pharmaceuticals

HISUN Pharmaceuticals and ShengZhao Pharmaceuticals jointly established a joint venture company to expand their international presence in the complex injectable drug field

HISUN announced that recently, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical, participated in the bidding work for the 11th batch of national centralized drug procurement organized by the Joint Procurement Office. According to the "Public Announcement of Proposed Winning Results for National Centralized Drug Procurement" issued by the Joint Procurement Office on October 28, 2025, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical, are proposed to win the bid for 3 products that fall within the scope of this centralized procurement

HISUN: Plans to win the bid for national centralized drug procurement

HISUN announced that the European Union has revoked the "GMP non-compliance declaration" for its Taizhou factory, which means that the factory is no longer in a state of GMP non-compliance. This move will have a positive impact on the company's product sales in the EU and other markets

HISUN: EU revokes the statement of non-compliance with GMP for Taizhou factory

HISUN announced that its product 1,4-butanedisulfonic acid adenosylmethionine has passed the U.S. Self-GRAS certification. This means that the product has undergone scientific evaluation and has obtained market access qualifications in the U.S., allowing it to be sold as a safe dietary ingredient in the U.S. and other international markets, further enriching the company's profit structure and laying the foundation for globalization

HISUN: 1,4-Butanedisulfonic acid adenosylmethionine has passed the US Self-GRAS certification

HISUN(600267.SH)

April 15 Midday Market Review: GEM Index Opens High and Falls, Closing Down 0.23%; Innovative Drug Concepts Rally Collectively

HISUN's revenue in 2025 is expected to be 10.55 billion yuan

Xinhua Pharmaceutical Wins NMPA Approval for New Electrolyte Injection

China's pet prescription food welcomes a breakthrough player

HISUN: Has cumulatively spent CNY 56.9915 million to repurchase 0.51% of its shares

On the morning of the second day of the National Conference in 2025: Shenghe Pharmaceutical, HISUN, and other pharmaceutical companies enter the venue

HISUN Pharmaceuticals and ShengZhao Pharmaceuticals jointly established a joint venture company to expand their international presence in the complex injectable drug field

HISUN: Plans to win the bid for national centralized drug procurement

HISUN: EU revokes the statement of non-compliance with GMP for Taizhou factory

HISUN: 1,4-Butanedisulfonic acid adenosylmethionine has passed the US Self-GRAS certification